Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Read More Share:linkedin| twitter| email

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

Read More Share:linkedin| twitter| email

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

Read More Share:linkedin| twitter| email

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

Read More Share:linkedin| twitter| email

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

May

02

JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS)

Read More Share:linkedin| twitter| email

Apr

01

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Read More Share:linkedin| twitter| email

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:linkedin| twitter| email

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More Share:linkedin| twitter| email

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)